Results 191 to 200 of about 179,279 (289)

Parathyroid carcinoma as an overlooked etiology of osteoporosis in postmenopausal women: a case report. [PDF]

Front Endocrinol (Lausanne)
Su J, Lei S, Jin M, Hu H, He W.
europepmc   +1 more source

Supplementary Material for: Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study

, 2018
Fabienne Schochter, Brigitte Rack, Marie Tzschaschel, A Polasik, Ulrich Andergassen, Elisabeth Trapp, Marianna Alunni‐Fabbroni, Andreas Schneeweiß, Volkmar Müller, Klaus Pantel, Josephine Gade, Ralf Lorenz, Mahdi Rezai, Hans Tesch, Ulrike Soeling, Tanja Fehm, Sven Mahner, Christian Schindlbeck, W. Lichtenegger, Matthias W. Beckmann, Peter A. Fasching, Wolfgang Janni, Friedl T.W.P., on behalf of the SUCCESS Study Group   +23 more
openalex   +1 more source

Postmenopausal uterine lesion

Saudi Journal of Medicine and Medical Sciences, 2018
Weam R Alsaeed, Layla S Albayyat, Tarek Elsharkawy   +2 more
openaire   +3 more sources

Impact of mono‐ or multitherapy on ocular surface health and quality of life after 5 years of follow‐up in the Glaucoma Intensive Treatment Study (GITS)

Acta Ophthalmologica, EarlyView.
Abstract Aim To evaluate the impact of initial mono‐ versus multitherapy on the ocular surface and related quality of life after 5 years follow‐up in the Glaucoma Intensive Treatment Study (GITS). Method The study included patients with primary open‐angle glaucoma and pseudoexfoliation glaucoma who completed 5‐year follow‐up in GITS.
Gauti Jóhannesson, Christina Lindén, Johan Aspberg, Sabina Andersson‐Geimer, Anders Heijl, Boel Bengtsson, Dorothea Peters   +6 more
wiley   +1 more source

Evaluation of salivary bone turnover markers and vitamin D as non-invasive, early predictive indicators of bone health in pre-, peri-, and post-menopausal women. [PDF]

BMC Womens Health
Mathangi R, Babu NA, Reshma A, Shankar K, Masthan KMK.   +4 more
europepmc   +1 more source

Cytochrome P450 1A1 influences obesity‐induced pulmonary hypertension

British Journal of Pharmacology, EarlyView.
Background and Purpose The contribution of obesity to pulmonary arterial hypertension (PAH) pathophysiology remains poorly understood. Adipose tissue synthesises estrogens via cytochrome P450 (CYP) 19A1 (aromatase), whereas circulating estrogens are metabolised in the lung by CYP1A1.
Joshua P. Dignam, Smriti Sharma, Gregor Aitchison, Ayman Gebril, Ioannis Stasinopoulos, Sofia Laforest, Chelbi Coyle, Ruth Andrew, Natalie Z. M. Homer, Sébastien Bonnet, Sandra Breuils‐Bonnet, Martin Wabitsch, Margaret R. MacLean   +12 more
wiley   +1 more source

Menopausal Status Associated With Docetaxel-Induced Vascular Dysfunction in Breast Cancer Patients. [PDF]

J Am Coll Cardiol
Szczepaniak P, Mikolajczyk TP, Jozefczuk E, Hodorowicz-Zaniewska D, Streb J, Jurczyk J, Nosalski R, Siedlinski M, Sajdak P, Brzuszkiewicz K, Gorski M, Tomaszewski M, Sulicka-Grodzicka J, Laksa I, Grodzicki T, Guzik TJ.   +15 more
europepmc   +1 more source

Critical role of the mast cell/tryptase/PAR2 axis in anastrozole‐induced pain

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Anastrozole, an aromatase inhibitor, is used to treat postmenopausal women with hormone receptor‐positive breast cancer, but also induces musculoskeletal pain and can lead to therapeutic regimen suspension. Aromatase inhibitors promote the release of pro‐inflammatory substances from sensitised nerve fibres, which might ...
Maria Fernanda Pessano Fialho, Raquel Tonello, Evelyne Silva Brum, Gabriela Becker, Nigel W. Bunnett, Sara Marchesan Oliveira   +5 more
wiley   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. [PDF]

Cureus
Graczyk NA, Bisschops J.
europepmc   +1 more source

Pembrolizumab for Early‐Stage Triple‐Negative Breast Cancer: KEYNOTE‐522 Japan Subgroup Analysis

Cancer Science, EarlyView.
In the global, phase 3 KEYNOTE‐522 study of high‐risk early‐stage triple‐negative breast cancer (TNBC), neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab improved efficacy outcomes versus neoadjuvant chemotherapy alone. In this analysis of Japanese participants from KEYNOTE‐522, neoadjuvant pembrolizumab plus chemotherapy ...
Masato Takahashi, Hirofumi Mukai, Toshimi Takano, Koichiro Tsugawa, Kenichi Inoue, Mitsuya Itoh, Junichiro Watanabe, Yuko Tanabe, Naohito Yamamoto, Yasuo Miyoshi, Kenichi Watanabe, Toru Mukohara, Yibin Kong, Masashi Shimura, Francisco Beca, Peter Schmid, Hiroji Iwata   +16 more
wiley   +1 more source